{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:32:16Z","timestamp":1762659136074},"reference-count":67,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.dld.2011.04.002","type":"journal-article","created":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T01:12:18Z","timestamp":1306113138000},"page":"850-855","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment"],"prefix":"10.1016","volume":"43","author":[{"given":"V\u00e9ronique","family":"Loustaud-Ratti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Babany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Alain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Tr\u00e9po","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"De Ledinghen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Zarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandrina","family":"Pinta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Sautereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2011.04.002_bib0005","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2011.04.002_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-2004-832927","article-title":"Pegylated interferon monotherapy for chronic hepatitis C","volume":"24","author":"Heathcote","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2011.04.002_bib0015","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1053\/j.gastro.2006.07.022","article-title":"Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin","volume":"131","author":"Bronowicki","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0020","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2011.04.002_bib0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mcp.2002.127112","article-title":"Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic\u2013pharmacodynamic models","volume":"72","author":"Jen","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0030","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.47.1.124-129.2003","article-title":"Ribavirin quantification in combination treatment of chronic hepatitis C","volume":"47","author":"Larrat","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2011.04.002_bib0035","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.22217","article-title":"Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C","volume":"47","author":"Loustaud-Ratti","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350801300401","article-title":"Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients","volume":"13","author":"Maynard","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0045","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0016-5085(94)90131-7","article-title":"A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C","volume":"107","author":"Brillanti","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0050","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-123-12-199512150-00001","article-title":"Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial","volume":"123","author":"Di Bisceglie","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2011.04.002_bib0055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2011.04.002_bib0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2036.2008.03705.x","article-title":"Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin","volume":"28","author":"Bain","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0065","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"Yu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.20563","article-title":"High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C","volume":"41","author":"Lindahl","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0075","first-page":"710A","article-title":"Individualized high dose ribavirin in combination with peginterferon to hepatitis C genotype 1 patients with previous non response","volume":"52","author":"Lindhal","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2011.04.002_bib0085","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2011.04.002_bib0090","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0168-8278(09)60052-0","article-title":"Activity of telaprevir alone or in combination with peginterferon alpha 2a and ribavirin in treatment naive genotype 2 and 3 hepatitis C patients: interim results of study C209","volume":"50","author":"Foster","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2011.04.002_bib0095","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(09)60012-X","article-title":"Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alpha 2 a and ribavirin in treatment na\u00efve genotype 4 HCV patients","volume":"50","author":"Benhamou","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2011.04.002_bib0100","first-page":"400A","article-title":"Dual, triple and quadruple combination treatment with a protease inhibitor (GS 9256) and a polymerase inhibitor (GS 9190) alone and in combination with ribavirin or Peginterferon\/ribavirin for up to 28 days in treatment naive, genotype 1 HCV subjects","volume":"52","author":"Zeuzem","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000090942","article-title":"Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy","volume":"76","author":"Donnerer","year":"2006","journal-title":"Pharmacology"},{"key":"10.1016\/j.dld.2011.04.002_bib0110","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/135965350701200815","article-title":"Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients","volume":"12","author":"Crespo","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0115","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.01399-09","article-title":"Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C","volume":"54","author":"Morello","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2011.04.002_bib0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000081741","article-title":"Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C","volume":"48","author":"Arase","year":"2005","journal-title":"Intervirology"},{"key":"10.1016\/j.dld.2011.04.002_bib0125","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/jmv.21227","article-title":"Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV","volume":"80","author":"Nicot","year":"2008","journal-title":"J Med Virol"},{"key":"10.1016\/j.dld.2011.04.002_bib0130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2893.2010.01303.x","article-title":"Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2\/3 infection","volume":"18","author":"Pedersen","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2011.04.002_bib0135","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3851\/IMP1560","article-title":"Plasma\/erythrocyte ribavirin \u00d7100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response","volume":"15","author":"Baiocchi","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0140","first-page":"400A","article-title":"Telprevir in combination with peginterferon alfa 2A and ribavirin for 24 or 48 weeks in treatment-na\u00efve genotype 1 HCV patients who achieved an extended rapid virological response: final results of phase 3 illuminate study","volume":"52","author":"Sherman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0145","first-page":"427A","article-title":"Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase III advance study","volume":"52","author":"Jacobson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0150","first-page":"402A","article-title":"Boceprevir combined with peginterferon\/ribavirin for treatment-naive patients with hepatitis C virus genotype 1: SPRINT 2 final results","volume":"52","author":"Poordad","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0155","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon\u2013alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0160","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.dld.2011.04.002_bib0170","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.dld.2011.04.002_bib0175","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.dld.2011.04.002_bib0180","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin","volume":"138","author":"McCarthy","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0185","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0190","first-page":"773A","article-title":"Differential association of a chromosome 19 single nucleotide (SNP RS12979860) to outcome (early virologic response\/sustained virologic response) in na\u00efve versus retreated HCV patients treated with IFN-based therapies","volume":"52","author":"Asselah","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0195","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2010.05.079","article-title":"An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response","volume":"139","author":"Mangia","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0200","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2010.07.041","article-title":"Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients","volume":"54","author":"Sarrazin","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2011.04.002_bib0205","doi-asserted-by":"crossref","first-page":"708A","DOI":"10.1002\/hep.23826","article-title":"Hepatitis C trials that combine investigational agents with pegylated interferon alfa should be stratified by IL28B genotype","volume":"52","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0210","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1172\/JCI40594","article-title":"Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV","volume":"121","author":"Casrouge","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.dld.2011.04.002_bib0215","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/hep.24056","article-title":"Quantitation of pretreatment serum interferon-\u03b3-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response","volume":"53","author":"Darling","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0220","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0225","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1046\/j.1365-2036.2002.01331.x","article-title":"Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in \u2018real world\u2019 patients with chronic hepatitis C","volume":"16","author":"Gaeta","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0230","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1053\/j.gastro.2010.07.059","article-title":"Virus treatment-related anemia is associated with higher sustained virologic response rate","volume":"139","author":"Sulkowski","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0235","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/MEG.0b013e32833e784d","article-title":"Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment","volume":"22","author":"Van Vlerken","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2011.04.002_bib0240","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.dld.2011.04.002_bib0245","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","article-title":"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0250","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3851\/IMP1609","article-title":"Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy","volume":"15","author":"Brochot","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0255","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/gast.2002.34175","article-title":"Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha","volume":"123","author":"Peck-Radosavljevic","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1572-0241.2005.40757.x","article-title":"HCV Natural History Study Group Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon\/ribavirin","volume":"100","author":"Balan","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2011.04.002_bib0265","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-2036.2010.04269.x","article-title":"Review article: optimizing SVR and management of the haematological side effects of peginterferon\/ribavirin antiviral therapy for HCV\u2014the role of epoetin. G-CSF and novel agents","volume":"31","author":"Mac Nicholas","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0270","first-page":"2491","article-title":"Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa","volume":"98","author":"Dieterich","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2011.04.002_bib0275","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1053\/j.gastro.2004.01.027","article-title":"Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study","volume":"126","author":"Afdhal","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.04.002_bib0280","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1572-0241.2005.41910.x","article-title":"Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C","volume":"100","author":"Stravitz","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2011.04.002_bib0285","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/lt.21332","article-title":"Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus","volume":"13","author":"Schecter","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2011.04.002_bib0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1086\/589243","article-title":"Erythropoiesis-stimulating agent use for anemia induced by interferon\u2013ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death","volume":"47","author":"Costiniuk","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2011.04.002_bib0295","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.21712","article-title":"Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha","volume":"46","author":"Shiffman","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0300","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/135965350501000605","article-title":"The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus","volume":"10","author":"Lebray","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2011.04.002_bib0305","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2893.2007.00956.x","article-title":"A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment","volume":"15","author":"Younossi","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2011.04.002_bib0310","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00007691-200010000-00010","article-title":"Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C","volume":"22","author":"Jen","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dld.2011.04.002_bib0315","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/656334","article-title":"Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon\u2013ribavirin therapy in patients with chronic hepatitis C virus infection","volume":"202","author":"Morello","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.dld.2011.04.002_bib0320","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2011.04.002_bib0325","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.24058","article-title":"Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir","volume":"53","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2011.04.002_bib0330","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dkn013","article-title":"The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV\/HCV-co-infected patients treated with ribavirin and pegylated interferon","volume":"6","author":"Aguilar Marucco","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.dld.2011.04.002_bib0335","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/QAI.0b013e3181b62858","article-title":"Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients","volume":"52","author":"Breilh","year":"2009","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865811001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865811001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T23:55:34Z","timestamp":1712447734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865811001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1590865811001265"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2011.04.002","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}